The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell carcinoma who partake in a separate clinical study featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future renal cell carcinoma patients and play an active role in advancing clinical research.
Study Type
OBSERVATIONAL
Enrollment
500
Power Life Sciences
San Francisco, California, United States
Number of patients who decide to participate in a renal cell carcinoma clinical study
Time frame: 3 months
Rate of patients who remain in renal cell carcinoma clinical trial to trial completion
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.